ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ALQGC Quantum Genomics

0.111
-0.0022 (-1.94%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Quantum Genomics EU:ALQGC Euronext Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0022 -1.94% 0.111 0.11 0.1196 0.1136 0.111 0.1134 42,774 16:40:00

Quantum Genomics Raises €8.6 Million in U.S. and Europe

24/03/2016 12:00pm

GlobeNewswire Inc.


Quantum Genomics (EU:ALQGC)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more Quantum Genomics Charts.

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company focused on the development of new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that it has completed a private placement with U.S. institutional investors totalling €5.54 million. Directly following the U.S. capital increase, the Company raised an additional €3.04 million through a public offering in Europe through existing shareholders, for a total of €8.6 million.

In these two placements, the Company issued 1,429,973 shares at €6.00 per share, and warrants to purchase an additional 714,986 shares at an exercise price of €7.75 per share for 30 months. The warrants, if fully exercised, would generate additional proceeds of €5.5 million. Participation in the European rights offering was open to shareholders of Quantum Genomics as of March 16, 2016.

“This capital increase is consistent with our expansion strategy, which includes the recently announced establishment of a U.S. Clinical Advisory Board and the opening of an office in New York on March 1st, 2016. The funds raised will enable us to further advance, in the U.S. and various European countries, the Phase II clinical trials of our products for the treatment of resistant hypertension and heart failure,” said Lionel Ségard, Chairman and Chief Executive Officer of Quantum Genomics.

Maxim Group LLC acted as the exclusive placement agent in the United States, and Invest Securities managed the subscriptions in France.

ABOUT QUANTUM GENOMICS

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.

Quantum Genomics is developing a new therapeutic approach based on BAPAI  (Brain Aminopeptidase A Inhibition).  This is the result of more than 20 years of academic research in the laboratories  of the Collège de France, INSERM, CNRS and the University of Paris Descartes.

Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC). The Company has offices in Paris, France and New York, NY, USA. For more information, please visit www.quantum-genomics.com.

CONTACTS
Quantum Genomics
Lionel Ségard
Chairman & Chief Executive Officer
+33 1 85 34 77 77

Quantum Genomics
Marc Karako
CFO – Investor Relations
+33 1 85 34 77 75
marc.karako@quantum-genomics.com

ACTUS finance et communication (Europe)
Jean-Michel Marmillon
Press Relations
+33 1 53 67 36 73
jmmarmillon@actus.fr

The Ruth Group (U.S.)
Lee Roth / Kirsten Thomas
Investor / Public Relations
+1 646-536-7012 / +1 508-280-6592

1 Year Quantum Genomics Chart

1 Year Quantum Genomics Chart

1 Month Quantum Genomics Chart

1 Month Quantum Genomics Chart